🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT06962371
Recruiting Not applicable

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

NCT06962371 · tracked via the Priya Life Science Australia tracker
Sponsor
Transverse Medical, Inc
Phase
Not applicable
Started
2025-04-07
Last updated
2025-05-08

Condition(s) studied

Transcatheter Aortic Valve Implantation (TAVI)Aortic Valve StenosisTranscatheter Aortic Valve Replacement

Investigational drug(s) / intervention(s)

cerebral embolic protection

cerebral embolic protection: Use of Transverse Medical Inc. Point-Guard CEP device.

Study summary

The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. The patient is ≥18 years of age; 2. The patient meets indications for Transcatheter Aortic Valve Replacement (TAVR); 3. The patient is willing to comply with protocol-specified follow-up evaluations; 4. The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board or Ethics Committee. Exclusion Criteria: 1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval). 2. Anatomy that precludes safe delivery and retrieval of the investigational device. 3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period. 4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up. 5. Patients with uncontrolled bleeding disorders. 6. Patients who are pregnant, as confirmed by a positive pregnancy test. General Exclusion Criteria 1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval). 2. Anatomy that precludes safe delivery and retrieval of the investigational device. 3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period. 4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up. 5. Patients with uncontrolled bleeding disorders. 5\. Patients who are pregnant, as confirmed by a positive pregnancy test. Magnetic resonance imaging exclusion criteria: 1. Body Mass Index (BMI) and/or total body weight precluding imaging in scanner. 2. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure). 3. High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., subjects with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block). 4. Existing or planned implantation of a pacemaker or defibrillator implantation within the first 3 days after TAVR. 5. Claustrophobia precluding MRI scanning.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Victorian Heart Hospital Clayton Victoria Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06962371 on ClinicalTrials.gov ↗ ← All trials in Australia